140 related articles for article (PubMed ID: 20005704)
1. Novel thioamide derivatives as neutral CB1 receptor antagonists.
Boström J; Olsson RI; Tholander J; Greasley PJ; Ryberg E; Nordberg H; Hjorth S; Cheng L
Bioorg Med Chem Lett; 2010 Jan; 20(2):479-82. PubMed ID: 20005704
[TBL] [Abstract][Full Text] [Related]
2. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.
Boström J; Berggren K; Elebring T; Greasley PJ; Wilstermann M
Bioorg Med Chem; 2007 Jun; 15(12):4077-84. PubMed ID: 17433696
[TBL] [Abstract][Full Text] [Related]
3. Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Seo HJ; Kim MJ; Song KS; Lee SH; Jung ME; Kim MS; Park HJ; Yoo J; Chang CH; Kim J; Lee J
Future Med Chem; 2009 Aug; 1(5):947-67. PubMed ID: 21426091
[TBL] [Abstract][Full Text] [Related]
4. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
[TBL] [Abstract][Full Text] [Related]
5. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
[TBL] [Abstract][Full Text] [Related]
6. Diaryl piperidines as CB1 receptor antagonists.
Scott JD; Li SW; Wang H; Xia Y; Jayne CL; Miller MW; Duffy RA; Boykow GC; Kowalski TJ; Spar BD; Stamford AW; Chackalamannil S; Lachowicz JE; Greenlee WJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):1278-83. PubMed ID: 20018510
[TBL] [Abstract][Full Text] [Related]
7. Substituted pyrimidines as cannabinoid CB1 receptor ligands.
Kim MJ; Kim JY; Seo HJ; Lee J; Lee SH; Kim MS; Kang J; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4692-7. PubMed ID: 19596576
[TBL] [Abstract][Full Text] [Related]
8. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor antagonists and obesity.
Black SC
Curr Opin Investig Drugs; 2004 Apr; 5(4):389-94. PubMed ID: 15134279
[TBL] [Abstract][Full Text] [Related]
10. Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.
Smith RA; Fathi Z; Achebe F; Akuche C; Brown SE; Choi S; Fan J; Jenkins S; Kluender HC; Konkar A; Lavoie R; Mays R; Natoli J; O'Connor SJ; Ortiz AA; Su N; Taing C; Tomlinson S; Tritto T; Wang G; Wirtz SN; Wong W; Yang XF; Ying S; Zhang Z
Bioorg Med Chem Lett; 2007 May; 17(10):2706-11. PubMed ID: 17383180
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
Lange JH; van der Neut MA; den Hartog AP; Wals HC; Hoogendoorn J; van Stuivenberg HH; van Vliet BJ; Kruse CG
Bioorg Med Chem Lett; 2010 Mar; 20(5):1752-7. PubMed ID: 20137935
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
15. Insights into the molecular requirements for the anti-obesity activity of a series of CB1 ligands.
Weber KC; De Lima EF; De Mello PH; Da Silva AB; Honório KM
Chem Biol Drug Des; 2010 Oct; 76(4):320-9. PubMed ID: 20887613
[TBL] [Abstract][Full Text] [Related]
16. Identification and hit-to-lead optimization of a novel class of CB1 antagonists.
Letourneau JJ; Jokiel P; Olson J; Riviello CM; Ho KK; McAleer L; Yang J; Swanson RN; Baker J; Cowley P; Edwards D; Ward N; Ohlmeyer MH; Webb ML
Bioorg Med Chem Lett; 2010 Sep; 20(18):5449-53. PubMed ID: 20719511
[TBL] [Abstract][Full Text] [Related]
17. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders.
Antel J; Gregory PC; Nordheim U
J Med Chem; 2006 Jul; 49(14):4008-16. PubMed ID: 16821760
[No Abstract] [Full Text] [Related]
18. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.
Kim JY; Seo HJ; Lee SH; Jung ME; Ahn K; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Jan; 19(1):142-5. PubMed ID: 19022666
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.
Pettersson H; Bülow A; Ek F; Jensen J; Ottesen LK; Fejzic A; Ma JN; Del Tredici AL; Currier EA; Gardell LR; Tabatabaei A; Craig D; McFarland K; Ott TR; Piu F; Burstein ES; Olsson R
J Med Chem; 2009 Apr; 52(7):1975-82. PubMed ID: 19338356
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
